Baird Reiterates Outperform Rating on Taysha Gene Therapies (TSHA); 'Encouraged by FDA Interactions'
Tweet Send to a Friend
Baird analyst Jack Allen reiterated an Outperform rating and $7.00 price target on Taysha Gene Therapies (NASDAQ: TSHA) saying they ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
